EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)
Dec 1, 2024, 00:00
10.1016/j.jval.2024.10.773
https://www.valueinhealthjournal.com/article/S1098-3015(24)03636-2/fulltext
Title :
EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)03636-2&doi=10.1016/j.jval.2024.10.773
First page :
Section Title :
Open access? :
No
Section Order :
10270